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Abstract
Introduction: Hepatitis C infection (HCV) is highly prevalent worldwide and has a well-known association with 
B-cell lymphoid malignancies. While several studies have demonstrated that antiviral therapy (AT) is effective 
to induce a complete hematological response in HCV-related low-grade B cell lymphoma, in HCV-related high-
grade B cell non-Hodgkin lymphomas such as diffuse large B cell lymphoma (DLBCL) chemotherapy is the only 
possible choice. However, the role of AT to reduce relapse of DLBCL after an effective chemotherapy containing 
rituximab (CT-R) has not been analyzed in previous studies. Therefore we analyzed whether patients with a sus-
tained virological response (SVR) to AT had over time a reduction of lymphoma relapse compared to no-SVR 
patients. 
Material and methods: The study included 21 consecutive HCV-infected patients affected by DLBCL. The pa-
tients were treated with AT (direct-acting antivirals or pegylated interferon alfa plus ribavirin) concomitantly or 
after CT-R. Over time, we evaluated relapse of DLBCL in patients treated with CT-R according to response to AT.
Results: An SVR was achieved in 16 of 21 patients. Five patients relapsed on AT with PegIFN/R (pegylated inter-
feron plus ribavirin). Over time lymphoma relapse was more frequent in patients without a virological response 
compared with patients with an SVR (RR = 12.0, 95% CI: 1.66-86, p < 0.01 Fisher’s exact test). 
Conclusions: AT during or after CT-R is an important strategy to prevent relapse of DLBCL in HCV patients when 
the patients have achieved an SVR. Our results suggest that eradication of HCV infection may result in long-term 
prevention of B-cell non-Hodgkin’s lymphoma relapse.
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the role of HCV in lymphomagenesis (“antigen-driven 
proliferation”) [3]. It was demonstrated in several stud-
ies as, in low-grade HCV-related marginal zone lym-
phoma, eradication of HCV through antiviral therapy 
(AT) led to regression of lymphoma in the majority of 
cases [4]. Diffuse large cell lymphoma is a high-grade 
lymphoma and chemotherapy is the first form of treat-
ment. The role of AT is less clearly defined. No sufficient 
data are available about the role of the new antiviral 
agents in DLBCL patients treated with chemotherapy 
containing rituximab (CT-R). The advent of direct- 
acting antivirals (DAAs) makes the treatment of HCV 
Introduction
Hepatitis C virus (HCV) is associated with a large 
spectrum on lymphoproliferative disorders. In non- 
Hodgkin’s lymphoma (NHL) prevalence of HCV in-
fection is estimated to be about 15%, which is approxi-
mately 8-10-fold higher than that reported in the gener-
al population (1.5%) [1]. The histologic subtypes more 
closely related to HCV are represented by diffuse large 
B cell lymphoma (DLBCL), marginal zone lymphoma, 
and lymphoplasmacytic lymphoma [2]. The etiologi-
cal link between HCV and DLBCL is probably due to 
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more appealing, especially in this difficult-to-treat pop-
ulation. The most recent updated hepatological (EASL) 
and hematological (NCCN) international guidelines 
suggest beginning the HCV treatment as the first thera-
peutic choice in the case of indolent lymphomas, but we 
lack a solid recommendation for DAAs in DLBCL due 
to the lack of data [5, 6]. 
Hence, we aimed to analyze the role of AT in pre-
venting the recurrence of DLBCL in HCV-infected 
patients treated with CT-R. DAAs’ efficacy and safety 
profile were also investigated. 
Material and methods 
The study cohort included 21 consecutive HCV- 
positive patients affected with DLBCL (12 males and 
7 females) referred to our tertiary center of hepatolo-
gy in Rome from January 2013 to December 2017, for 
a clinical and therapeutic evaluation for HCV treatment 
with a DAA or with Peg/RBV. The patients studied were 
under simultaneous observation for management of 
NHL disease at the hematology service of our hospital. 
All patients were treated with different chemothera-
peutic regimens, all including rituximab. The patients 
were also treated with AT (DAAs or pegylated interfer-
on plus ribavirin) concomitantly or after CT-R. All the 
patients were tested for liver fibrosis with a  transient 
elastography measurement with a Echosens FibroScan 
device, model 502 (Echosens, Paris, France), or with 
liver biopsy (Ishak score) prior to the start of AT.
During antiviral treatment all the patients were fol-
lowed up, with weekly evaluations of their liver func-
tion and monthly evaluation of HCV RNA. Adverse 
reactions to AT were recorded. In accordance with the 
aim of the study follow-up data were prospectively col-
lected for up to five years after treatment conclusion, in 
order to define the disease-free-survival.
Sustained virological response (SVR) was defined as 
the disappearance of serum HCV RNA 12 or 24 weeks 
after the end of therapy according to type of AT. 
Inclusion criteria were: diagnosis of aggressive 
DLBCL and indication for antineoplastic treatment 
(patients underwent the best treatment of choice, in ac-
cordance with the hematological guidelines in force at 
the time of diagnosis of neoplasia), together with geno-
type HCV active infection at the onset of the neoplastic 
disease. Exclusion criteria were: indolent or low-grade 
lymphoma, current and/or previous HBV infection, 
presence of clinical decompensated cirrhosis.
All patients gave their written informed consent 
to the data collection and the conduction of the study. 
The present study was conducted in compliance with 
the Declaration of Helsinki.
The NHL stage was defined by the Ann Arbor 
classification according to physical examination, to-
tal body computed tomography scan, bone marrow 
biopsy and biopsy of the organ involved. Complete 
hematological remission was defined as the absence 
of disease for at least one month after the end of che-
motherapy. The statistical analysis was performed us-
ing IBM-SPSS (Statistical Package for Social Science) 
v.21 for McIntosh. Patients with SVR and without 
SVR were compared using the Mann-Whitney U test. 
The cumulative risk for relapse of DLBCL during the 
follow-up was assessed through a Kaplan-Meier curve 
and the comparison between DLBCL patients with or 
without SVR was performed through the log-rank test.
Results
The patients’ characteristics of our study popula-
tion are reported in Table 1. Liver fibrosis was assessed 
prior to the start of treatment with AT by performing 
transient elastography or liver biopsy: 2 patients had 
mild liver fibrosis (< 7.0 kPa), 13 had liver stiffness that 
was compatible with moderate fibrosis (7.0-9.5 kPa), 
4 patients had severe fibrosis (9.5-12.5 kPa). Child-
Pugh A  liver cirrhosis (> 12.5 kPa) was revealed in 
2 patients. Genotype 1 was the most represented gen-
otype (57.1%). All patients had a stage IV DLBCL. We 
evaluated relapse of DLBCL after CT-R in patients 
with or without an SVR to AT. An SVR was achieved in 
16 of 21 patients. Five patients treated with PegIFN/
RBV combination therapy did not achieve an SVR 
and relapse of the neoplastic disease was noted in 
4 patients. In our series, lymphoma relapse was more 
frequent in patients without a  virological response 
compared to patients who achieved an SVR (RR = 9.0, 
95% CI: 1.27-63.00, p < 0.02 Mann-Whitney U  test). 
No patients treated with DAAs during chemotherapy 
presented transaminase flare or liver function decom-
pensation. All the characteristics of the patients are re-
ported in Table 1. 
The actuarial cumulative probability of being free 
from relapse of the neoplastic disease at 12, 24 and 
48 months was 100%, 94% and 94% in SVR patients 
and 82%, 50% and 20% in no-SVR patients, respective-
ly (Figure 1).
Discussion
While different studies have shown a benefit of AT 
in HCV-related low-grade lymphoma in terms of lym-
phoma remission, only a few studies have demonstrat-
ed in HCV-positive DLBCL efficacy of AT always com-
bined with CT-R in order to reinforce the remission 
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and to reduce relapse of neoplastic disease. Per sico 
et al. demonstrated that in 20 HCV-positive patients 
undergoing CT-R for DLBCL and treated with DAAs 
there was better overall survival and disease-free sur-
vival in 52 weeks of follow-up compared to a control 
group of HCV-positive patients treated only with CT 
[7]. However, in this study 45% of the control group 
was treated with a  CT regimen without rituximab, 
which could have influenced the results. Several stud-
ies have shown that disease-free survival (DFS) and 
overall survival (OS) is lower in patients with DLBCL 
treated with CT not containing rituximab compared 
to patients treated with CT-R (20% vs. 36.5) [8, 9]. For 
this reason it is difficult in this study to extrapolate 
the conclusion about DFS and OS due to the hetero-
geneous group of patients. Our brief report has the 
strength of confirming in a small series of patients the 
effective role of SVR after AT for the long-term remis-
sion of neoplastic disease, especially in those patients 
treated with DAAs.









CT HR after 
CT-R
AT Time AT SVR Hem.
Rel/FU (m)
1 23/M 3 1b F2 R-CHOP CR Peg/RBV Post Y No/48
2 44/F 4 2 F2 R-CHOP CR Peg/RBV Post Y No/52
3 68/M 4 2 F2 R-CHOP CR Peg/RBV Post No Yes/48
4 71/M 4 2 F3 R-VCP CR Peg/RBV Post No Yes/18
5 50/M 4 1b F1 R-CHOP CR Peg/RBV Post No Yes/43
6 74/F 4 1b F3 R-CHOP CR Peg/RBV Post Y Yes/20
7 58/M 4 1 a F2 R-CHOP CR Peg/RBV Post Y No/58
8 45/M 4 1b F1 R-CHOP CR Peg/RBV Post No Yes/18
9 72/M 4 2 F2 R-VCP CR Peg/RBV Post No No/57
10 64/M 4 1b F3 R-CHOP CR Peg/RBV Post Y No/69
11 59/F 4 1 a F2 R-CHOP CR Peg/RBV Post Y No/46
12 40/F 4 1b F2 R-VCP CR SOF/SMV Post Y No/26
13 54/M 4 3 F2 R-CHOP CR SOF/DCV During Y No/20
14 55/M 4 1 a F4 R-CHOP CR SOF/SMV Post Y No/22
15 74/F 4 2 F2 R-CHOP CR SOF/RBV During Y No/23
16 55/M 4 1 a F3 R-CHOP CR SOF/SMV Post Y No/28
17 40/M 4 3 F2 R-CHOP CR SOF/LDV Post Y No/20
18 67/F 4 1b F2 R-CHOP CR Omb-Par/R-Das Post Y No/22
19 52/F 4 3 F2 R-BEND CR SOF/DCV During Y No/22
20 59/M 4 4 F4 R-CHOP CR SOF/DCV/RBV During Y No/32
21 66/F 4 1b F2 R-CHOP CR SOF/SMV During Y No/28
Pt – patient, AT – antiviral treatment, HR after CT-R – hematological response after chemotherapy containing rituximab, CR – complete hematological response, R-CHOP – rituximab plus 
cyclophosphamide, vincristine, doxorubicin, vincristine, prednisolone, R-VCP – rituximab plus cyclophosphamide, vincristine, prednisolone, Peg – pegylated interferon, RBV – ribavirin, 
Post – post-chemotherapy, During – during chemotherapy, SVR – sustained virological response, SOF – sofosbuvir, SMV – simeprevir, DCV – daclatasvir, LDV – ledipasvir, FU – follow-up from 
the end of AT, Omb – ombitasvir, Par – paritaprevir, R-Das – ritonavir/dasabuvir, BEND – bendamustine
Fig. 1. Comparison of 50 months relapse of diffuse large B cell lymphoma 
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Hosry et al. demonstrated that HCV-positive patients 
never treated with AT had DLBCL more refractory to 
first-line chemotherapy than that in HCV-negative pa-
tients (33% vs. 17%; p = 0.05) and had more progressive 
lymphoma, though not statistically significantly, com-
pared to HCV-negative patients (50% vs. 32%; p = 0.09) 
or patients given AT (50% vs. 27%; p = 0.06). This result 
could suggest that DLBCL in HCV-infected patients 
is more refractory to CT-R compared to HCV-nega-
tive patients. Moreover, they found that patients never 
given AT had worse 5-year OS rates than did treated 
patients (HR = 2.3, 95% CI: 1.01-5.30, p = 0.04). In this 
study there was not found a reduction of lymphoma re-
lapse after CT-R between HCV-treated and non-treat-
ed patients (41% vs. 46%, p = 0.7) [10]. We have some 
concern about this result because the authors did not 
analyze the lymphoma relapse rate between HCV-treat-
ed patients who achieved a SVR and those who did not. 
In our opinion the real impact of AT on lymphoma 
relapse is difficult to extrapolate in this study. Michot 
et al. observed a positive association between AT and 
OS in DLBCL patients. They stated that AT reinforced 
the results of a successful CT-R [11]. It is our opinion 
that AT during or after chemotherapy is an important 
strategy to prevent relapse of DLBCL in HCV-infected 
patients when the patients achieved a SVR. This hypo-
thesis may be based in part on sustained B cell activa-
tion and inhibition of B cell apoptosis by HCV [12]. 
Eradication of hepatitis C can turn off the persistent ac-
tivation of B lymphocytes by HCV. Another important 
consideration must be done. Furthermore, we have to 
consider that the use of chemotherapy in combination 
with rituximab for the treatment of DLBCL in patients 
infected with HCV can produce different degrees of 
liver dysfunction [13]. A rare case of cholestatic hepa-
titis C was also published; it occurred in a patient with 
DLBCL and HCV infection [14]. DAAs demonstrated 
excellent safety and seem not to have pharmacological 
interactions with CT-R. Several reports have described 
cases of DLBCL treated at the same time with CT-R 
and DAAs without adverse events and a  reduction 
of liver toxicity [15, 16]. Cicero in the trial defending 
Sextus Roscius, who was accused of patricide, asked 
“Cui bono?” (Who benefits?). This same question needs 
to be answered in HCV-infected patients with DLBCL 
in the era of DAAs. We believe the answer lies both in 
the prevention of relapse of DLBCL and reduction of 
liver damage during CT-R, but also in the prevention of 
HCV-related complications after cure of DLBCL. 
In conclusion, our study confirms that in HCV- 
associated DLBCL, AT reduces the lymphoma relapse 
rate when an SVR is achieved. Furthermore, a  DAA 
combined with CHOP-R is safe and seems to reduce 
the risk of hepatitis C flare and hepatic toxicity due to 
immunochemotherapy.
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